Indeed, in the cardiovascular outcome trial (CVOT) for semaglutide, SUSTAIN 6 a relatively short (two-year) and small (3,297 individuals) preregistration trial (an extensive CVOT in obese individuals without T2DM (SELECT) is expected to complete in 2024) HbA 1c was powerfully and durably reduced
administration owing to both DPP-4 resistance and a delay in kidney removal because of its large size
Malhotra, A., Grunstein, R
Two products may appear similar in strength and cost, yet differ significantly in documentation, testing visibility, and batch verification standards
GLP-1 medications such as Ozempic and Wegovy have helped many people achieve significant weight loss and better overall health
Gastrointestinal effects Nausea is the most commonly reported side effect with both compounds individually